Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [31] Core Insights - On January 30, 2023, the report highlights that the company has signed a strategic R&D cooperation and licensing agreement with AstraZeneca to develop innovative long-acting peptide drugs using its proprietary sustained-release drug delivery technology and peptide drug AI discovery platform [3] - AstraZeneca will gain global exclusive rights to the company's weight management product portfolio, which includes a clinical-ready project SYH2082 and three preclinical projects targeting obesity and weight-related issues [3] - The company is set to receive $1.2 billion in upfront payments, with potential milestone payments of up to $3.5 billion for R&D and up to $13.8 billion in sales milestone payments, along with a double-digit percentage royalty on annual net sales of the licensed products [3] Summary by Sections Industry Overview - The report emphasizes the increasing recognition of Chinese innovative pharmaceutical companies by international multinational corporations (MNCs), particularly through the recent collaboration with AstraZeneca [4] - The report also notes AstraZeneca's plan to invest $15 billion in China by 2030 to expand drug manufacturing and R&D, leveraging China's scientific capabilities and manufacturing strengths [4] Investment Strategy - The report suggests that the global competitiveness of Chinese innovative pharmaceutical companies is continuously improving, with a focus on potential treatment areas such as metabolic diseases, chronic diseases, and central nervous system disorders [5] - It recommends paying attention to emerging fields like small nucleic acid drugs, radioactive drugs, and CAR-T therapies, highlighting specific companies to watch [5] Market Performance - The pharmaceutical sector experienced a decline of 3.31% last week, ranking 20th among 28 industries, while the Hong Kong pharmaceutical sector fell by 2.98% [9][30] - The report indicates that the valuation of the pharmaceutical sector is at 32.45 times (TTM), with a premium of 15.83% compared to the overall A-shares [23]

股票研究 /[Table_Date] 2026.02.01 持续推荐创新药械产业链 [Table_Industry] 医药 ——国泰海通医药 2026 年 2 月月报 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 郑琴(分析师) | 021-23219808 | zhengqin@gtht.com | S0880525040108 | | 谈嘉程(分析师) | 021-38038429 | tanjiacheng@gtht.com | S0880523070004 | 本报告导读： 持续推荐创新药械及产业链。 投资要点： | [Table_Invest] | | | --- | --- | | 评级： | 增持 | [Table_Report] 相关报告 医药《V940 五年随访数据披露，mRNA 肿瘤疫 苗长期价值验证》2026.01.30 医药《支持政策不断，持续推荐创新药械产业 链》202 ...

股票研究 /[Table_Date] 2026.02.01 持续推荐创新药械产业链 [Table_Industry] 医药 ——国泰海通医药 2026 年 2 月月报 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 郑琴(分析师) | 021-23219808 | zhengqin@gtht.com | S0880525040108 | | 谈嘉程(分析师) | 021-38038429 | tanjiacheng@gtht.com | S0880523070004 | 本报告导读： 持续推荐创新药械及产业链。 投资要点： | [Table_Invest] | | | --- | --- | | 评级： | 增持 | [Table_Report] 相关报告 医药《V940 五年随访数据披露，mRNA 肿瘤疫 苗长期价值验证》2026.01.30 医药《支持政策不断，持续推荐创新药械产业 链》202 ...

中国创新药出海BD再获里程碑式突破！ 1月30日，石药集团宣布已与全球生物制药领导者阿斯利康签订战略研发合作与授权协议，以利用集团 专有的缓释给药技术平台及多肽药物AI发现平台，开发创新长效多肽药物。若后续所有研发及销售里 程碑均达成，石药集团方面有权获得总计高达185亿美元的款项。 据不完全统计，本次交易刷新了中国药企BD交易总金额最高纪录，超过了此前启德医药与 Biohaven&AimedBio达成的一笔130亿美元交易。其12亿美元的预付款，仅次于此前三生制药与辉瑞就 PD-1/VEGF达成的数额。 不过，二级市场反应不佳，石药集团股价高开低走，盘中一度狂泻近13%，收跌10.2%。什么原因？分 析人士指出，或系多方面因素叠加影响。 从石药集团股价近日表现来看，市场可能提前定价。在此次协议公告前，石药集团已连续多日强势上 涨，尤其在1月28日，股价单日大涨6.14%创年内新高。公告发布后，部分资金可能选择获利了结，形 成"利好兑现"式抛压。 从业绩贡献来看，尽管协议总金额高达185亿美元，但预付款为12亿美元，其余173亿美元为研发与销售 里程碑付款，需在未来数年、多个临床阶段成功推进后方可兑现，短期现 ...

Core Insights - BeOne Medicines AG (NASDAQ:ONC) is highlighted as a promising healthcare stock for 2026, showcasing significant advancements in its pipeline development [1] Pipeline Development - The company’s BRUKINSA, a tyrosine kinase inhibitor, has demonstrated a 74% six-year progression-free survival rate in treatment-naïve chronic lymphocytic leukemia (CLL), significantly outperforming the 32% rate of bendamustine plus rituximab [2] - Sonrotoclax, a BCL2 inhibitor, has received regulatory approval with an impressive overall response rate of 86% in heavily pretreated CLL patients [2] - BeOne Medicines is advancing 15 new molecular entities into clinical trials and plans to introduce an additional 8 to 10 candidates [2] Market Performance and Projections - Citizens has reiterated a Market Perform rating for BeOne Medicines with a price target of $396, citing strong efficacy data from a phase 3 trial in gastric cancer patients [3] - The anticipated approval of sonrotoclax is expected to lead to further global approvals, while Brukinsa is projected to generate $3.8 billion in revenue by 2025 [3] Company Overview - BeOne Medicines AG is a biotechnology firm focused on the discovery, development, and commercialization of innovative and affordable oncology treatments, known for products like Brukinsa and Tevimbra [4]

Core Viewpoint - The CDMO (Contract Development and Manufacturing Organization) business of multinational companies in China is not just shrinking but appears to be disappearing, with only a few remaining players like Boehringer Ingelheim still operating in the market [2][10]. Group 1: Current State of CDMO in China - The CDMO business in China has seen a significant decline, with major players like Lonza and Thermo Fisher Scientific facing operational challenges and even selling their facilities [5][6][8]. - Boehringer Ingelheim remains one of the few foreign CDMO companies still active in China, primarily due to securing a contract for the production of BeiGene's PD-1 drug [10]. - The CDMO market in China is experiencing a transformation, with many foreign companies exiting or downsizing their operations due to insufficient orders and market conditions [7][10]. Group 2: Market Dynamics and Trends - The implementation of the 2019 Drug Administration Law in China marked a turning point for the CDMO market, allowing for a separation of production and marketing licenses, thus lowering barriers for research-focused pharmaceutical companies [12]. - Despite the advantages of a large workforce and lower costs in China, many foreign CDMO companies have struggled to establish a foothold due to high pricing models that do not align with local market conditions [13][14]. - The Chinese CDMO market has grown significantly, with a compound annual growth rate of 39.9% from 2018 to 2023, increasing from 16 billion RMB to 85.9 billion RMB, and is expected to reach 208.4 billion RMB by 2028 [16]. Group 3: Future Outlook - Domestic CDMO companies are increasingly matching or surpassing the capabilities of foreign counterparts, offering higher efficiency and lower prices, which positions them favorably in the market [16][17]. - The evolution of the Chinese CDMO industry has transitioned from reliance on foreign technology and policy support to a focus on technological development and global capacity expansion [16].

Core Insights - The CDMO (Contract Development and Manufacturing Organization) business of multinational companies in China is experiencing significant decline, with many exiting the market entirely [1][8] - The Chinese CDMO market is growing rapidly, with a compound annual growth rate of 39.9% from 2018 to 2023, and is expected to reach 208.4 billion RMB by 2028 [16] Group 1: Multinational CDMO Operations in China - Multinational companies like Lonza, Thermo Fisher, and Merck have faced challenges in their CDMO operations in China, with many either closing facilities or selling them off [4][5][6] - Lonza's Guangzhou factory, which was operational for only three years, was sold to a local company due to insufficient orders [4] - Thermo Fisher's factory in Hangzhou is struggling with low order volumes, and its future remains uncertain [5][6] Group 2: Local CDMO Developments - Zhaoyan Biotech's new manufacturing base in Guangzhou, which focuses on large molecule CDMO, signifies a strategic move to enhance capacity and create a collaborative platform for biopharmaceutical innovation in Southeast Asia [3] - Local companies are increasingly building their own production capabilities, reducing reliance on foreign CDMO services [14] Group 3: Market Dynamics and Trends - The introduction of the MAH (Marketing Authorization Holder) system in 2019 has lowered production barriers, allowing more companies to utilize CDMO services [11] - Despite the advantages of a large workforce and lower costs, foreign CDMOs have struggled to establish a foothold in China due to high pricing models that do not align with local market conditions [12][13] - The efficiency and cost-effectiveness of Chinese CDMOs are becoming competitive with their foreign counterparts, leading to a shift in market dynamics [15][16]

Core Viewpoint - The strategic collaboration between Shijiazhuang Pharmaceutical Group and AstraZeneca marks a significant milestone in the outbound business development (BD) of Chinese innovative drugs, with a potential total payment of up to $18.5 billion, setting a new record for BD transactions in the Chinese pharmaceutical industry [1][3]. Group 1: Transaction Details - Shijiazhuang Pharmaceutical has signed a strategic R&D cooperation and licensing agreement with AstraZeneca, utilizing its proprietary sustained-release drug delivery technology and peptide drug AI discovery platform to develop innovative long-acting peptide drugs [1]. - The total potential payment of $18.5 billion includes an upfront payment of $1.2 billion, with the remaining $17.3 billion contingent on achieving various R&D and sales milestones over the coming years [3]. Group 2: Market Reaction - Despite the significant deal, Shijiazhuang Pharmaceutical's stock experienced a sharp decline, dropping nearly 13% intraday and closing down 10.2%, attributed to profit-taking after a strong pre-announcement stock performance [1][3]. - The overall market sentiment was also negative, with major indices in Hong Kong, including the Hang Seng Index and the Hang Seng Biotechnology Index, falling over 2%, impacting the performance of other leading Chinese biopharmaceutical companies [3]. Group 3: Industry Outlook - Analysts suggest that the core logic of domestic innovative drugs remains solid, indicating a favorable window for investment as the BD of Chinese companies accelerates and the price gap for innovative drugs between China and the U.S. narrows, presenting significant long-term growth potential [5]. - The Hong Kong Stock Connect innovative drug ETF (520880) has seen substantial net subscriptions, indicating ongoing investor interest despite recent market volatility [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2026年1月23 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二百四十六名承授人授 出涉及合共21,034股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的受限制股份單位 於2026年1月23日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二百 四十六名承授人合共21,034股美國存託股份受限制股份單位。該等受限制股份單 位相當於273,442股股份，約佔本公告之日公司發行股份總數的0.02%。 授出受限制股份單位詳情 受限制股份單位詳情如下： 1 授出日期： 2026年1月23日 承授人數目： 二百四十六名 已授出受限制股份單位涉及的 相關股份數目： 273,44 ...

声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 作者：公告君 有投资者在互动平台向百济神州提问："您好，请问贵司为什么美股和A股的利息收入和所得税会差异 如此大（都以百万人民币计），比如21年美股的利息收入为-15.8百万美元，约为-110百万人民币，而A 股年报的利息收入为44.1百万人民币。是否存在口径/资本化的差异？" 针对上述提问，百济神州回应称："尊敬的投资者，您好！公司美股和A股报表分别按美国公认会计原 则和中国企业会计准则编制，详情请参见A股财务报告之'境内外会计准则下会计数据差异'章节。感谢 您的关注！" ...